Mallika Imwong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7591524/publications.pdf

Version: 2024-02-01

124 papers	14,249 citations	41344 49 h-index	21540 114 g-index
136 all docs	136 docs citations	136 times ranked	8820 citing authors

#	Article	IF	Citations
1	Artemisinin Resistance inPlasmodium falciparumMalaria. New England Journal of Medicine, 2009, 361, 455-467.	27.0	2,873
2	Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
3	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	21.4	515
4	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	27.8	450
5	Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 2013, 45, 648-655.	21.4	424
6	The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infectious Diseases, The, 2017, 17, 491-497.	9.1	371
7	Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 670-679.	4.0	368
8	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	9.1	363
9	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science, 2015, 347, 431-435.	12.6	362
10	A Major Genome Region Underlying Artemisinin Resistance in Malaria. Science, 2012, 336, 79-82.	12.6	334
11	Two Nonrecombining Sympatric Forms of the Human Malaria ParasitePlasmodium ovaleOccur Globally. Journal of Infectious Diseases, 2010, 201, 1544-1550.	4.0	310
12	Relapses ofPlasmodium vivaxInfection Usually Result from Activation of Heterologous Hypnozoites. Journal of Infectious Diseases, 2007, 195, 927-933.	4.0	266
13	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	9.1	252
14	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infectious Diseases, The, 2019, 19, 943-951.	9.1	219
15	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE, 2009, 4, e4551.	2.5	212
16	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	13.7	182
17	High-Throughput Ultrasensitive Molecular Techniques for Quantifying Low-Density Malaria Parasitemias. Journal of Clinical Microbiology, 2014, 52, 3303-3309.	3.9	181
18	Declining Efficacy of Artemisinin Combination Therapy AgainstP. FalciparumMalaria on the Thaiâ€“Myanmar Border (2003â€“2013): The Role of Parasite Genetic Factors. Clinical Infectious Diseases, 2016, 63, 784-791.	5.8	178

#	Article	IF	Citations
19	Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar. PLoS ONE, 2013, 8, e57689.	2.5	177
20	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infectious Diseases, The, 2010, 10, 673-681.	9.1	168
21	The epidemiology of subclinical malariaÂinfections in South-East Asia: findings from cross-sectional surveys in Thailandâ€“Myanmar border areas, Cambodia, and Vietnam. Malaria Journal, 2015, 14, 381.	2.3	163
22	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	9.1	147
23	Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. International Journal for Parasitology, 2007, 37, 1013-1022.	3.1	140
24	Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infectious Diseases, The, 2017, 17, 1022-1023.	9.1	136
25	Association of Genetic Mutations in Plasmodium vivax dhfr with Resistance to Sulfadoxine-Pyrimethamine: Geographical and Clinical Correlates. Antimicrobial Agents and Chemotherapy, 2001, 45, 3122-3127.	3.2	131
26	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet, The, 2018, 391, 1916-1926.	13.7	131
27	Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malaria Journal, 2005, 4, 20.	2.3	128
28	Novel Point Mutations in the Dihydrofolate Reductase Gene of Plasmodium vivax : Evidence for Sequential Selection by Drug Pressure. Antimicrobial Agents and Chemotherapy, 2003, 47, 1514-1521.	3.2	124
29	Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi. Journal of Infectious Diseases, 2019, 219, 695-702.	4.0	117
30	The genetic diversity of Plasmodium vivax populations. Trends in Parasitology, 2003, 19, 220-226.	3.3	115
31	Exploring the Contribution of Candidate Genes to Artemisinin Resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2010, 54, 2886-2892.	3.2	110
32	Numerical Distributions of Parasite Densities During Asymptomatic Malaria. Journal of Infectious Diseases, 2016, 213, 1322-1329.	4.0	108
33	Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1540-1550.	1.4	108
34	The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS Medicine, 2019, 16, e1002745.	8.4	105
35	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infectious Diseases, The, 2020, 20, 1470-1480.	9.1	94
36	Plasmodium falciparum pfmdr1 Amplification, Mefloquine Resistance, and Parasite Fitness. Antimicrobial Agents and Chemotherapy, 2009, 53, 1509-1515.	3.2	88

#	Article	IF	Citations
37	The First Plasmodium vivax Relapses of Life Are Usually Genetically Homologous. Journal of Infectious Diseases, 2012, 205, 680-683.	4.0	78
38	Genetic diversity of Plasmodium vivax in Kolkata, India. Malaria Journal, 2006, 5, 71.	2.3	74
39	Gene Amplification of the Multidrug Resistance 1 Gene of Plasmodium vivax Isolates from Thailand, Laos, and Myanmar. Antimicrobial Agents and Chemotherapy, 2008, 52, 2657-2659.	3.2	74
40	Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Tropical Medicine and International Health, 2008, 13, 91-98.	2.3	73
41	Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar. Wellcome Open Research, 2017, 2, 81.	1.8	71
42	Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Molecular and Biochemical Parasitology, 2002, 119, 63-73.	1.1	70
43	Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nature Communications, 2019, 10, 5595.	12.8	70
44	Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malaria Journal, 2010, 9, 308.	2.3	69
45	Limited Polymorphism in the Dihydropteroate Synthetase Gene (dhps) of Plasmodium vivax Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2005, 49, 4393-4395.	3.2	63
46	Population Genetic Analysis of Plasmodium falciparum Parasites Using a Customized Illumina GoldenGate Genotyping Assay. PLoS ONE, 2011, 6, e20251.	2.5	63
47	Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. Malaria Journal, 2016, 15, 181.	2.3	54
48	Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malaria Journal, 2011, 10, 113.	2.3	53
49	Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malaria Journal, 2010, 9, 105.	2.3	52
50	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2018, 67, 1543-1549.	5.8	52
51	Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. Malaria Journal, 2013, 12, 289.	2.3	51
52	An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand. Scientific Reports, 2015, 5, 17412.	3.3	50
53	Contribution of Asymptomatic Plasmodium Infections to the Transmission of Malaria in Kayin State, Myanmar. Journal of Infectious Diseases, 2019, 219, 1499-1509.	4.0	50
54	Operational Performance of a Plasmodium falciparum Ultrasensitive Rapid Diagnostic Test for Detection of Asymptomatic Infections in Eastern Myanmar. Journal of Clinical Microbiology, 2018, 56, .	3.9	49

#	Article	IF	Citations
55	Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2019, 68, 1311-1319.	5.8	49
56	Four human Plasmodium species quantification using droplet digital PCR. PLoS ONE, 2017, 12, e0175771.	2.5	49
57	A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Clinical Infectious Diseases, 2018, 67, 817-826.	5.8	48
58	Effects of Different Antimalarial Drugs on Gametocyte Carriage in P. Vivax Malaria. American Journal of Tropical Medicine and Hygiene, 2008, 79, 378-384.	1.4	46
59	Asymptomatic Plasmodium infections in 18 villages of southern Savannakhet Province, Lao PDR (Laos). Malaria Journal, 2016, 15, 296.	2.3	45
60	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria Journal, 2016, 15, 185.	2.3	43
61	Genotyping of Plasmodium vivax Reveals Both Short and Long Latency Relapse Patterns in Kolkata. PLoS ONE, 2012, 7, e39645.	2.5	41
62	Submicroscopic Plasmodium prevalence in relation to malaria incidence in 20 villages in western Cambodia. Malaria Journal, 2017, 16, 56.	2.3	40
63	Long-term storage limits PCR-based analyses of malaria parasites in archival dried blood spots. Malaria Journal, 2012, 11, 339.	2.3	39
64	Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malaria Journal, 2015, 14, 319.	2.3	39
65	A trade off between catalytic activity and protein stability determines the clinical manifestations of glucose-6-phosphate dehydrogenase (G6PD) deficiency. International Journal of Biological Macromolecules, 2017, 104, 145-156.	7.5	35
66	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
67	High genetic polymorphism of relapsing P. vivax isolates in northwest Colombia. Acta Tropica, 2011, 119, 23-29.	2.0	31
68	Simultaneous Quantification of Plasmodium Antigens and Host Factor C-Reactive Protein in Asymptomatic Individuals with Confirmed Malaria by Use of a Novel Multiplex Immunoassay. Journal of Clinical Microbiology, 2019, 57, .	3.9	31
69	Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration. Malaria Journal, 2016, 15, 541.	2.3	30
70	Detailed functional analysis of two clinical glucose-6-phosphate dehydrogenase (G6PD) variants, G6PDViangchan and G6PDViangchan+Mahidol: Decreased stability and catalytic efficiency contribute to the clinical phenotype. Molecular Genetics and Metabolism, 2016, 118, 84-91.	1.1	30
71	Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. American Journal of Tropical Medicine and Hygiene, 2008, 79, 378-84.	1.4	29
72	K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Malaria Journal, 2016, 15, 110.	2.3	27

#	Article	IF	Citations
73	Effectiveness and safety of 3 and 5Âday courses of artemetherâ€“lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malaria Journal, 2018, 17, 258.	2.3	27
74	Artesunateâ€“dapsoneâ€“proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 142-149.	1.8	26
75	Genetic Analysis of the Dihydrofolate Reductase-Thymidylate Synthase Gene from Geographically Diverse Isolates of Plasmodium malariae. Antimicrobial Agents and Chemotherapy, 2007, 51, 3523-3530.	3.2	24
76	A multi-level spatial analysis of clinical malaria and subclinical Plasmodium infections in Pailin Province, Cambodia. Heliyon, 2017, 3, e00447.	3.2	23
77	History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia. Malaria Journal, 2016, 15, 240.	2.3	21
78	Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. Antimicrobial Agents and Chemotherapy, 2021, 65, e0112121.	3.2	21
79	Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. Malaria Journal, 2017, 16, 480.	2.3	20
80	The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisinâ€“piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal, 2018, 17, 405.	2.3	18
81	Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. Journal of Infectious Diseases, 2019, 220, 448-456.	4.0	17
82	Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. PLoS ONE, 2016, 11, e0149519.	2.5	17
83	Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. Malaria Journal, 2018, 17, 427.	2.3	16
84	Poor response to artesunate treatment in two patients with severe malaria on the Thaiâ€“Myanmar border. Malaria Journal, 2018, 17, 30.	2.3	16
85	Plasmodium vivax: Polymerase Chain Reaction Amplification Artifacts Limit the Suitability of pvgam1 as a Genetic Marker. Experimental Parasitology, 2001, 99, 175-179.	1.2	13
86	A Population Survey of the Glucose-6-Phosphate Dehydrogenase (G6PD) 563C>T (Mediterranean) Mutation in Afghanistan. PLoS ONE, 2014, 9, e88605.	2.5	13
87	Efficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in E. coli. Protein Expression and Purification, 2015, 107, 68-75.	1.3	13
88	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
89	Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. PLoS ONE, 2016, 11, e0158656.	2.5	13
90	Chloroquineâ€“Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1782-1787.	1.4	13

#	Article	IF	Citations
91	Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. Malaria Journal, 2013, 12, 96.	2.3	12
92	Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia. Malaria Journal, 2016, 15, 484.	2.3	12
93	Genetic polymorphisms in the circumsporozoite protein of Plasmodium malariae show a geographical bias. Malaria Journal, 2018, 17, 269.	2.3	12
94	Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016. Malaria Journal, 2020, 19, 107.	2.3	11
95	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2021, 65, e0130221.	3.2	10
96	Genetic diversity of three surface protein genes in Plasmodium malariae from three Asian countries. Malaria Journal, 2018, 17, 24.	2.3	9
97	Prevalence of Plasmodium falciparum Molecular Markers of Antimalarial Drug Resistance in a Residual Malaria Focus Area in Sabah, Malaysia. PLoS ONE, 2016, 11, e0165515.	2.5	9
98	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Malaria Journal, 2016, 15, 121.	2.3	8
99	Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes. Malaria Journal, 2017, 16, 228.	2.3	8
100	Utility of Plasmodium falciparum DNA from rapid diagnostic test kits for molecular analysis and whole genome amplification. Malaria Journal, 2020, 19, 193.	2.3	8
101	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1579-1589.	9.1	8
102	Plasmodium vivax genetic diversity and heterozygosity in blood samples and resulting oocysts at the Thaiâ€“Myanmar border. Malaria Journal, 2017, 16, 355.	2.3	7
103	Genetic dissociation of three antigenic genes in Plasmodium ovale curtisi and Plasmodium ovale wallikeri. PLoS ONE, 2019, 14, e0217795.	2.5	7
104	The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos. Malaria Journal, 2019, 18, 449.	2.3	7
105	Functional and structural analysis of double and triple mutants reveals the contribution of protein instability to clinical manifestations of G6PD variants. International Journal of Biological Macromolecules, 2020, 158, 884-893.	7.5	7
106	Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia. BMJ Open, 2021, 11, e045900.	1.9	7
107	Clustering of malaria in households in the Greater Mekong Subregion: operational implications for reactive case detection. Malaria Journal, 2021, 20, 351.	2.3	7
108	Use of Blood Smears and Dried Blood Spots for Polymerase Chain Reactionâ€“Based Detection and Quantification of Bacterial Infection and Plasmodium falciparum in Severely Ill Febrile African Children. American Journal of Tropical Medicine and Hygiene, 2016, 94, 322-326.	1.4	6

#	Article	IF	Citations
109	Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparumÂhave only a transient impact on Plasmodium vivax: Findings from randomised controlled trials. PLoS ONE, 2020, 15, e0228190.	2.5	6
110	Genetic Variability of Plasmodium malariae dihydropteroate synthase (dhps) in Four Asian Countries. PLoS ONE, 2014, 9, e93942.	2.5	6
111	Combined effects of double mutations on catalytic activity and structural stability contribute to clinical manifestations of glucose-6-phosphate dehydrogenase deficiency. Scientific Reports, 2021, 11, 24307.	3.3	6
112	Genome-wide microsatellite characteristics of five human Plasmodium species, focusing on Plasmodium malariae and P. ovale curtisi. Parasite, 2020, 27, 34.	2.0	5
113	Molecular surveillance for operationally relevant genetic polymorphisms in Plasmodium falciparum in Southern Chad, 2016â€“2017. Malaria Journal, 2022, 21, 83.	2.3	5
114	Limited Polymorphism of the Kelch Propeller Domain in Plasmodium malariae and P. ovale Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2016, 60, 4055-4062.	3.2	4
115	Polymorphisms in Pvkelch12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. Malaria Journal, 2019, 18, 114.	2.3	4
116	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. Malaria Journal, 2020, 19, 4.	2.3	4
117	Measurement of gene amplifications related to drug resistance in Plasmodium falciparum using droplet digital PCR. Malaria Journal, 2021, 20, 120.	2.3	4
118	Assessment of Plasmodium antigens and CRP in dried blood spots with multiplex malaria array. Journal of Parasitic Diseases, 2021, 45, 479-489.	1.0	4
119	Genetic population of Plasmodium knowlesi during pre-malaria elimination in Thailand. Malaria Journal, 2021, 20, 454.	2.3	4
120	Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017. Malaria Journal, 2020, 19, 251.	2.3	3
121	Polymorphic markers for identification of parasite population in Plasmodium malariae. Malaria Journal, 2020, 19, 48.	2.3	3
122	Comparative analysis of targeted next-generation sequencing for Plasmodium falciparum drug resistance markers. Scientific Reports, 2022, 12, 5563.	3.3	3
123	Genetic analysis of the orthologous crt and mdr1 genes in Plasmodium malariae from Thailand and Myanmar. Malaria Journal, 2020, 19, 315.	2.3	1
124	Artemisinin resistance in Myanmar â€“ Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 1002-1003.	9.1	0